Key result
A 39-year-old female with primary hepatic angiosarcoma underwent a liver transplant and adjuvant chemotherapy, remaining disease-free for 12 months before tumor recurrence.
Why the study?
Primary hepatic angiosarcoma is a rare malignant liver tumor with an extremely poor prognosis, difficult diagnosis, and unclear treatment protocols.
Case Report (n=1)
No
This case report highlights a rare presentation of primary hepatic angiosarcoma treated with liver transplant and sequential chemo-immunotherapy, achieving survival beyond 12 months.
Documents rare non-resectable PHA with acute liver failure; leaves open standardized diagnostic and therapeutic protocols.
Primary hepatic angiosarcoma (PHA) is a rare malignant tumor of the liver with an extremely poor prognosis even after diagnosis and treatment. It is difficult to diagnose due to a lack of disease-specific clinical features, tumor markers, or imaging findings. Due to its rarity of occurrence, treatment protocols are not yet clear. We present a rare case of PHA in a 39-year-old female who presented with right upper quadrant abdominal pain and was found to have acute liver failure and a non-resectable liver mass. She underwent a liver transplant (LT) as PHA could not be diagnosed before the transplant. She received chemotherapy and had done well for 12 months until her carcinoma relapsed. She underwent a repeat cycle of chemotherapy; however, her tumor continued to progress and is now undergoing a trial of immunotherapy.
No takes yet. Share an insight, caveat, or question.
Aziz et al. (2025) conducted a case report in Primary hepatic angiosarcoma (n=1). Liver transplant and chemotherapy was evaluated on Disease recurrence. A 39-year-old female with primary hepatic angiosarcoma underwent a liver transplant and adjuvant chemotherapy, remaining disease-free for 12 months before tumor recurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: